- Home
- BEEP vs CHRS Comparison
BEEP vs CHRS Comparison
Compare BEEP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEP
- CHRS
- Stock Information
- Founded
- BEEP 2015
- CHRS 2010
- Country
- BEEP United States
- CHRS United States
- Employees
- BEEP N/A
- CHRS N/A
- Industry
- BEEP Blank Checks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BEEP Finance
- CHRS Health Care
- Exchange
- BEEP Nasdaq
- CHRS Nasdaq
- Market Cap
- BEEP 150.7M
- CHRS 159.2M
- IPO Year
- BEEP N/A
- CHRS 2014
- Fundamental
- Price
- BEEP $3.61
- CHRS $1.35
- Analyst Decision
- BEEP Strong Buy
- CHRS Strong Buy
- Analyst Count
- BEEP 2
- CHRS 4
- Target Price
- BEEP $6.75
- CHRS $4.51
- AVG Volume (30 Days)
- BEEP 34.0K
- CHRS 1.2M
- Earning Date
- BEEP 11-11-2025
- CHRS 11-05-2025
- Dividend Yield
- BEEP N/A
- CHRS N/A
- EPS Growth
- BEEP N/A
- CHRS N/A
- EPS
- BEEP N/A
- CHRS 1.55
- Revenue
- BEEP $36,142,000.00
- CHRS $272,209,000.00
- Revenue This Year
- BEEP $1.29
- CHRS N/A
- Revenue Next Year
- BEEP $5.56
- CHRS $109.48
- P/E Ratio
- BEEP N/A
- CHRS $0.87
- Revenue Growth
- BEEP 6.15
- CHRS 52.33
- 52 Week Low
- BEEP $2.65
- CHRS $0.66
- 52 Week High
- BEEP $4.86
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- BEEP 47.33
- CHRS 64.99
- Support Level
- BEEP $3.25
- CHRS $1.23
- Resistance Level
- BEEP $3.78
- CHRS $1.40
- Average True Range (ATR)
- BEEP 0.25
- CHRS 0.08
- MACD
- BEEP -0.04
- CHRS -0.00
- Stochastic Oscillator
- BEEP 46.78
- CHRS 72.13
About BEEP Mobile Infrastructure Corporation
Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States. The company owns forty three parking facilities in twenty one separate markets throughout the United States, with a total of approximately fifteen thousand seven hundred parking spaces. It operates in a single reportable segment: parking. The company derives majority of revenue from Percentage rental income.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.